Cargando…

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

BACKGROUND: In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Dennis, Binks, Sophie, Nicholas, Jennifer M, Frost, Chris, Cardoso, M Jorge, Ourselin, Sebastien, Wilkie, David, Nicholas, Richard, Chataway, Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507768/ https://www.ncbi.nlm.nih.gov/pubmed/28600189 http://dx.doi.org/10.1016/S1474-4422(17)30113-8

Ejemplares similares

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
por: Williams, Thomas, et al.
Publicado: (2022)

Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2019)

Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial
por: Williams, Thomas E., et al.
Publicado: (2022)

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
por: Connick, Peter, et al.
Publicado: (2018)

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
por: Chataway, Jeremy, et al.
Publicado: (2020)

Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis
por: Lewin, Alex, et al.
Publicado: (2016)

Secondary Progressive Multiple Sclerosis: New Insights
por: Cree, Bruce A.C., et al.
Publicado: (2021)

Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials
por: Williams, Thomas, et al.
Publicado: (2022)

Pioglitazone/simvastatin: Acute kidney injury secondary to rhabdomyolysis: case report
Publicado: (2021)

Severe rhabdomyolysis and acute renal failure secondary to the use of simvastatin in undiagnosed hypothyroidism
por: Qari, F. A.
Publicado: (2008)

Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis
por: Pousinis, Petros, et al.
Publicado: (2020)

Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS
por: Bittner, Frank, et al.
Publicado: (2017)

Editorial: Plant secondary metabolites: Potential therapeutic implications in neuropsychiatric disorders
por: Rodríguez-Landa, Juan Francisco, et al.
Publicado: (2023)

Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study
por: Carroll, Camille B, et al.
Publicado: (2019)

The Involvement of Secondary Neuronal Damage in the Development of Neuropsychiatric Disorders Following Brain Insults
por: Chen, Yun, et al.
Publicado: (2014)

Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
por: Vesterinen, Hanna M., et al.
Publicado: (2015)

Exploring Secondary Metabolite Profiles of Stachybotrys spp. by LC-MS/MS
por: Jagels, Annika, et al.
Publicado: (2019)

The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol
por: Schooneveldt, Yvette L., et al.
Publicado: (2021)

Secondary Amyloidosis Associated with Multiple Sclerosis
por: Kang, Seok Jae, et al.
Publicado: (2009)

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors
por: Beard, Emma, et al.
Publicado: (2021)

Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Lipoic acid in secondary progressive MS: A randomized controlled pilot trial
por: Spain, Rebecca, et al.
Publicado: (2017)

Estimation of the Content of Selected Active Substances in Primary and Secondary Herbal Brews by UV-VIS and GC-MS Spectroscopic Analyses
por: Wyrostek, Jakub, et al.
Publicado: (2020)

A Placebo-Controlled Trial of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome
por: Wassif, Christopher A., et al.
Publicado: (2016)

Secondary Metabolite Profiling of Species of the Genus Usnea by UHPLC-ESI-OT-MS-MS
por: Salgado, Francisco, et al.
Publicado: (2017)

LC-MS-Based Metabolomics Study of Marine Bacterial Secondary Metabolite and Antibiotic Production in Salinispora arenicola
por: Bose, Utpal, et al.
Publicado: (2015)

The enigma of primary and secondary encapsulating peritoneal sclerosis
por: Allam, Hisham, et al.
Publicado: (2016)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

The relationship between multiple sclerosis and neuropsychiatric syndromes
por: McLoughlin, James, et al.
Publicado: (2017)

Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
por: Silveira, Celeste, et al.
Publicado: (2019)

Cognitive and neuropsychiatric endophenotypes in amyotrophic lateral sclerosis
por: Costello, Emmet, et al.
Publicado: (2023)

Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway
por: Al-rasheed, Nouf M, et al.
Publicado: (2015)

The genetics of neuropsychiatric disorders
por: Bray, Nicholas J., et al.
Publicado: (2018)

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo‐Controlled, Phase II Study
por: Denton, Christopher P., et al.
Publicado: (2017)

Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC–ESI–MS/MS
por: Ramesh, B., et al.
Publicado: (2015)

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS
por: Fan, Zaiwen, et al.
Publicado: (2023)

MS/MS spectral tag-based annotation of non-targeted profile of plant secondary metabolites
por: Matsuda, Fumio, et al.
Publicado: (2009)

A case report: Catatonic symptoms secondary to systemic lupus erythematosus with multiple infections: neuropsychiatric or “mimickers?”
por: Lv, Lizeyu, et al.
Publicado: (2023)

The roles of JAK2/STAT3 signaling in fusion of the secondary palate
por: Yoshida, Naoki, et al.
Publicado: (2023)

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study
por: Marshall, Ian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_race0avujbnk4102r4ciue1rvb